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boronary artery disease (CAD) is the principal cause of
orbidity and mortality in industrialized nations. In ap-
roximately one-half of the individuals, the initial presen-
ation of CAD is either myocardial infarction (MI) or
udden death. Unfortunately, conventional risk factor as-
essment only predicts 65% to 80% of future cardiovascular
vents, leaving many middle-aged and older individuals to
anifest a major cardiovascular event despite being classi-
ed as low risk by the Framingham risk estimate.
See page 1258
One landmark study showed that just 25% of patients
ho presented with an MI before the age of 65 would have
ualified for pharmacotherapy with a statin the day before
heir MI based on their Framingham risk profile (1). The
ercentage of women qualifying for aspirin and statin
herapy before their MI is even lower, because women
ounger than 70 years of age are very unlikely to reach the
0% risk of a hard event threshold (2). Considering the
imits of current screening strategies based on traditional
isk factors, clinicians need to explore other strategies to
ore accurately capture this vulnerable population and
educe the likelihood of downstream adverse events.
Many noninvasive imaging tests have emerged as candi-
ates for further refining our ability to detect those patients
arboring advanced subclinical atherosclerosis. Among
hese, coronary artery calcification (CAC) testing has con-
incingly been demonstrated to provide additional prognos-
ic information over office-based CAD risk assessment, and
here has been a trend in recent years toward the acceptance
f a role for selective use of CAC testing in “intermediate-
isk” adults (3).
The authors of a recent meta-analysis (4) demonstrated
hat patients without any CAC (approximately 50% of
ndividuals screened) are extremely unlikely to have signif-
cant CAD, have myocardial perfusion abnormalities, or
evelop an acute coronary syndrome; they are deemed to be
t negligible risk for a CAD event over the next 5 years.
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.s
From the Johns Hopkins Ciccarone Center for Prevention of Heart Disease,
altimore, Maryland.elective use of CAC testing may, thus, be helpful to
dentify those requiring more aggressive pharmacotherapy
nd, perhaps more important, to identify the larger subset of
ndividuals at very low risk for whom further cardiac testing
nd pharmacotherapy with aspirin and statin may be safely
e avoided in the short term (5).
From a societal standpoint, it is not only important to
stablish the ability of CAC testing to predict future CAD
utcomes but also vital to demonstrate that the use of
therosclerosis imaging for adults will not lead to a cascade
f costly downstream testing (6). In addition to the monu-
ental rate of morbidity and mortality that is directly
elated to atherosclerotic vascular disease, the total eco-
omic cost of cardiovascular disease is already estimated to
e$475 billion (7). This issue becomes even more relevant
n the current economic climate, and there are active
overnmental efforts to curtail health care expenditures.
Does atherosclerotic testing significantly impact down-
tream cost? In this issue of the Journal, Shaw et al. (8)
resent the results of the EISNER (Early Identification of
ubclinical Atherosclerosis by Noninvasive Imaging Re-
earch) study, a timely and landmark investigation that
ttempts to address this question by examining the down-
tream effect of screening for subclinical atherosclerosis. The
uthors sought to determine how CAC testing affects the
conomics of resource consumption and procedural costs.
In this study, the majority of individuals had either no
AC (57%) or minimal CAC scores of 1 to 10 (21%), with
ery few individuals with advanced atherosclerosis (CAC
01 to 1,000: 6%; CAC 1,000: 2%). The study is unique
n that for the first time, costs incurred from downstream
oninvasive and invasive procedures (as well as treatment
osts, including medications, revascularization, and hospi-
alization) were examined.
The results were reassuring in that the likelihood of pursu-
ng further testing given no or minimal coronary atherosclero-
is was negligible. Most of the downstream resource utilization
whether appropriate by current guidelines or not) was in the
resence of very high CAC scores. Importantly, invasive
rocedures were not performed immediately after CAC test-
ng, and they were performed in a stepwise manner preceded
y functional imaging with either exercise stress testing or
tress myocardial perfusion imaging.
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September 29, 2009:1268–70 Selective Use of Coronary Artery Calcium ScreeningThe study findings also may provide fuel to critics who fear
hat those with significantly increased CAC scores will be sent
or more testing without any indication that this would have a
ositive impact on saving lives (9). Although current guidelines
ecommend managing these patients aggressively with phar-
acotherapy and more intensified lifestyle modification, the
esults of the EISNER study demonstrate a greater likelihood
f these individuals undergoing noninvasive studies leading to
nvasive coronary angiography (ICA) and ultimately costly
evascularizations.
This is a concern in light of the COURAGE (Clinical
utcomes Utilizing Revascularization and Aggressive Drug
valuation) trial results, in which aggressive medical and
ifestyle management in patients with advanced stable CAD
ed to similar outcomes compared with an interventional
lus optimal medical and lifestyle approach (10,11). How-
ver, the costly procedures were primarily limited to the
roup with a CAC score of 400 (8% of population
creened). In addition, although abnormal findings resulted
n more testing, the absolute increase in testing is not high
hen the overall population is taken into account.
Among every 100 individuals screened for CAC, only 8
ould have CAC scores 400, with the majority undergo-
ng stress echocardiograms or myocardial perfusion testing
5 to 7 individuals) and nearly one-half undergoing ICA
approximately 4 individuals). In comparison, only 14 indi-
iduals of the 78 of 100 screened with CAC scores of 0 to
0 would undergo some sort of stress imaging, and only 1
ill proceed with ICA in 6 years of follow-up. For the majority
f individuals with no or low CAC (78% of those screened
ith CAC), the median costs were minimal ($25 to $35),
ostly incurred by ECG testing, which is often part of the
nitial assessment of individuals with hypertension (a feature
bserved in nearly 60% of this low-risk group).
Overall, of all individuals undergoing CAC testing,
early 20% had some form of stress imaging performed,
hereas 7% had an ICA. An interesting question not
ddressed by EISNER is whether these procedures would
ave taken place even in the absence of CAC testing. For
xample, it is unclear whether atypical anginal symptoms
rompted some of these individuals to undergo further
esting, an outcome that might have occurred even without
priori CAC testing. In addition, the study does not
rovide any comparison with other well-established CAD
creening tools such as carotid intima-medial thickness or
easurements of biomarkers such as high-sensitivity
-reactive protein. Future studies also are needed to show
hether various imaging/nonimaging risk-stratifying strat-
gies produce comparable downstream outcomes.
However, the EISNER study is a starting point in our
fforts to understand how best to use limited resources for
HD prevention. From a national health care expenditures
tandpoint, it may well provide justification for restricting
ggressive CAD management to those with at least mod-
rate subclinical atherosclerosis, which is observed in ap-
roximately 10% to 15% of middle-aged adults. In MESA bMulti-Ethnic Study of Atherosclerosis), only 9% of total
vents occurred over a median of 4 years in 50% of
ndividuals who had no detectable CAC, whereas 91% were
een in the other one-half having varying degrees of CAC
12). Similar findings were reported by Blaha et al. (5) in
hich during a follow-up of 13 years, only 6% of all deaths
ere recorded among those with an absence of CAC. Many
hysicians tend to overtreat patients in this “intermediate-
isk” group because of their uncertainty about future cardio-
ascular events.
In ASCOT (Anglo-Scandinavian Cardiac Outcomes
rial), in which hypertensive individuals with at least 3
AD risk factors were randomized to statin or placebo, 93
ersons had to be treated for a mean of 3.3 years to prevent
single cardiac event (13). Thus, treating all intermediate-
isk persons is highly cost-inefficient, and these patients
end to have poor long-term compliance with therapy. On
he basis of the MESA study, if we narrow our focus to
hose with a CAC 100 (only 25% of the population),
e can identify a subgroup in whom 63% of all coronary
eart disease (CHD) events would occur in short-term
ollow-up (13). Separating the subset of individuals with
bsent or low CAC and, thus, a very low risk of CHD
vents and focusing on those individuals with a high
therosclerotic burden may in the end limit an unsustain-
ble health care cost spiral.
Of all tests available for risk stratification, CAC superiorly
ivides patients into 2 clear subgroups of high and low future
HD risk than carotid intima-media thickness testing (14).
he results of the EISNER study alleviate the fear that such a
trategy will inevitably lead to high downstream costs. In light
f this, we hope that the various stakeholders in determining
ealth care resource allocation will move in the direction of
ddressing whether selective use of atherosclerosis imaging
hould play any role in halting the epidemic of atherosclerotic
ascular disease by better refining whichmiddle-aged and older
dults are truly at relatively high risk versus very low risk for a
VD event during the next 5 to 10 years.
The EISNER study provides further evidence for the
rgency of a randomized trial that compares the current
raditional risk factors-based approach with one supple-
ented by subclinical atherosclerotic screening to determine
hether this approach can save lives in a manner that is at
east moderately cost effective. This study does show that
creening costs will beget more costs; testing produces more
han the upfront cost of a procedure. In this regard, we
pplaud the recent efforts of the National Heart, Lung, and
lood Institute to initiate a dialogue on how to assess the
ocietal utility of such screening tests and look forward to
he outcome of these discussions. How best to deploy CAC
creening, more intensive lifestyle changes, earlier initiation
f aspirin, and statin therapy is quickly approaching a
rillion-dollar question! The sooner we find the answer, the
etter.
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